1. Home
  2. IIIN vs FULC Comparison

IIIN vs FULC Comparison

Compare IIIN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IIIN

Insteel Industries Inc.

HOLD

Current Price

$30.57

Market Cap

739.2M

Sector

Industrials

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$6.89

Market Cap

718.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IIIN
FULC
Founded
1953
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
739.2M
718.4M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
IIIN
FULC
Price
$30.57
$6.89
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$16.38
AVG Volume (30 Days)
103.2K
1.2M
Earning Date
04-16-2026
04-30-2026
Dividend Yield
3.59%
N/A
EPS Growth
112.12
N/A
EPS
0.39
N/A
Revenue
$647,706,000.00
N/A
Revenue This Year
$14.20
N/A
Revenue Next Year
$6.82
N/A
P/E Ratio
$80.13
N/A
Revenue Growth
22.39
N/A
52 Week Low
$22.49
$2.32
52 Week High
$41.64
$15.74

Technical Indicators

Market Signals
Indicator
IIIN
FULC
Relative Strength Index (RSI) 28.19 29.67
Support Level $30.23 $6.33
Resistance Level $32.50 $7.28
Average True Range (ATR) 1.06 0.47
MACD -0.44 -0.06
Stochastic Oscillator 8.18 10.38

Price Performance

Historical Comparison
IIIN
FULC

About IIIN Insteel Industries Inc.

Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Share on Social Networks: